Alumis (NASDAQ:ALMS) Shares Gap Up After Analyst Upgrade

Alumis Inc. (NASDAQ:ALMS) shares gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $18.00 to $32.00. The stock had previously closed at $16.23, but opened at $17.39. Guggenheim currently has a buy rating on the stock. Alumis shares last traded at $17.3610, with a volume of 2,599,676 shares changing hands.

ALMS has been the subject of a number of other reports. Leerink Partners set a $32.00 price target on Alumis in a report on Tuesday. Oppenheimer restated an “outperform” rating and set a $50.00 price objective on shares of Alumis in a research report on Tuesday. Morgan Stanley restated an “overweight” rating and issued a $33.00 target price on shares of Alumis in a report on Wednesday. HC Wainwright lifted their price target on shares of Alumis from $14.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, Citigroup reissued an “outperform” rating on shares of Alumis in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.33.

Insider Activity at Alumis

In other Alumis news, Director Srinivas Akkaraju acquired 186,377 shares of the company’s stock in a transaction on Friday, December 5th. The shares were bought at an average cost of $9.84 per share, for a total transaction of $1,833,949.68. Following the completion of the purchase, the director owned 1,265,253 shares in the company, valued at $12,450,089.52. This trade represents a 17.28% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Management Vi bought 190,500 shares of Alumis stock in a transaction dated Wednesday, November 19th. The stock was acquired at an average cost of $6.56 per share, with a total value of $1,249,680.00. Following the completion of the acquisition, the insider directly owned 2,542,003 shares of the company’s stock, valued at approximately $16,675,539.68. The trade was a 8.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 2,788,875 shares of company stock worth $18,352,357 in the last 90 days. 40.70% of the stock is owned by insiders.

Key Headlines Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Phase 3 topline: Both ONWARD Phase 3 trials met all primary and secondary endpoints with strong skin‑clearance results (~65% PASI90 and >40% PASI100 on average at Week 24) and a favorable safety profile; Alumis plans an NDA submission in H2‑2026 — this is the main fundamental catalyst behind the rally. Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
• Positive Sentiment: Market reaction: Media reports and trading pushed ALMS to a record intraday high with very heavy volume as investors priced in a potential competitor to J&J’s oral psoriasis offerings — momentum and attention are fueling short‑term buying. Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars
• Positive Sentiment: Analyst upgrade/target lift: Guggenheim raised its price target from $18 to $32 and initiated/maintained a Buy, signaling institutional analyst confidence and implying substantial upside versus pre‑news levels. That upgrade supports further investor interest. ALMS: Alumis price target raised by Guggenheim
• Neutral Sentiment: Insider buying & social buzz: Public summaries note multiple insider purchases and active social/media discussion, which can sustain momentum but do not guarantee long‑term value creation; treat as sentiment support rather than proof of commercial success. Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results
• Negative Sentiment: Planned $175M underwritten equity offering: Alumis announced a proposed public offering of common stock to raise $175M — this improves cash runway for regulatory/launch activities but creates near‑term dilution risk and can cap post‑deal upside. Alumis Announces Proposed Public Offering of Common Stock

Institutional Trading of Alumis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after purchasing an additional 4,894 shares during the last quarter. Kera Capital Partners Inc. acquired a new stake in shares of Alumis during the second quarter worth $32,000. Police & Firemen s Retirement System of New Jersey grew its position in Alumis by 199.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock valued at $32,000 after buying an additional 7,165 shares during the last quarter. New York State Common Retirement Fund increased its stake in Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after buying an additional 7,467 shares during the period. Finally, Western Wealth Management LLC acquired a new position in Alumis in the 2nd quarter valued at $36,000.

Alumis Stock Performance

The company has a market cap of $1.86 billion, a PE ratio of -4.35 and a beta of -2.09. The stock’s 50-day simple moving average is $8.38 and its 200 day simple moving average is $5.62.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The firm had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. On average, sell-side analysts predict that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.